Invention Grant
US08168659B2 1, 5-diphenyl-3-benzylamino-1, 5-dihydropyrrolidin-2-one as CB1 receptor modulators
失效
1,5-二苯基-3-苄基氨基-1,5-二氢吡咯烷-2-酮作为CB1受体调节剂
- Patent Title: 1, 5-diphenyl-3-benzylamino-1, 5-dihydropyrrolidin-2-one as CB1 receptor modulators
- Patent Title (中): 1,5-二苯基-3-苄基氨基-1,5-二氢吡咯烷-2-酮作为CB1受体调节剂
-
Application No.: US12441570Application Date: 2007-10-22
-
Publication No.: US08168659B2Publication Date: 2012-05-01
- Inventor: David Scott Coffey , Jingdan Hu , Stacy Jo Keding , Joseph Herman Krushinski, Jr. , John Mehnert Schaus , David Edward Tupper
- Applicant: David Scott Coffey , Jingdan Hu , Stacy Jo Keding , Joseph Herman Krushinski, Jr. , John Mehnert Schaus , David Edward Tupper
- Applicant Address: US IN Indianapolis
- Assignee: Eli Lilly and Company
- Current Assignee: Eli Lilly and Company
- Current Assignee Address: US IN Indianapolis
- Agent R. Craig Tucker
- International Application: PCT/US2007/082042 WO 20071022
- International Announcement: WO2008/070306 WO 20080612
- Main IPC: A61K31/4439
- IPC: A61K31/4439 ; C07D401/12
Abstract:
Compounds and pharmaceutical compositions comprising compounds of the Formula as CB1 receptor inverse agonists useful for reducing body weight in mammals, treating cognitive impairment associated with schizophrenia, and mitigating treatment emergent weight gain observed during treatment with antipsychotics.
Public/Granted literature
- US20090275618A1 1, 5-DIPHENYL-3-BENZYLAMINO-1, 5-DIHYDROPYRROLIDIN-2-ONE AS CB1 RECEPTOR MODULATORS Public/Granted day:2009-11-05
Information query
IPC分类:
